Impact of gender in clinicopathological features of Xp11.2 translocation renal cell carcinoma and clear cell renal cell carcinoma

doi:10.3877/cma.j.issn.1674-3253.2023.02.002

Abstract

Abstract:

Objective

To investigate the impact of gender in the clinicopathological features of Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) and clear cell renal cell carcinoma (ccRCC).

Methods

The clinical data of 53 patients who underwent surgery for Xp11.2 tRCC in Nanjing Drum Tower Hospital from June 2007 to August 2020 were retrospectively analyzed. A total of 173 patients with ccRCC were matched according to tumor diameter and operation time. The differences in clinicopathological characteristics of male and female patients with Xp11.2 tRCC and ccRCC were compared, and the related indicators and prognosis of the two groups of renal cancer patients were further compared.

Results

The Xp11.2 tRCC group had young and female incidence advantages, while ccRCC was more common in elder and male patients. In the Xp11.2 tRCC group, the male and female patients were different significantly in terms of laterality (P=0.010). In the ccRCC group, the male patients had higher levels in terms of T stage (P=0.022) and AJCC stage (P=0.029). There were significant differences between the Xp11.2 tRCC group and the ccRCC group in terms of gender, age of onset, surgical method, T stage, AJCC stage and nuclear grade (P<0.05). Survival analysis revealed that there was no statistical difference between male and female patients in Xp11.2 tRCC group (P>0.05), while the overall survival of males in ccRCC patients was shorter than that of females (P<0.05).

Conclusions

Compared with ccRCC, Xp11.2 tRCC is more likely to occur in young and female patients, which is a more aggressive subtype of renal cell carcinoma. Sex may be an important factor affecting the pathogenesis, pathological characteristics and prognosis of Xp11.2 tRCC.

Key words: Renal carcinoma, TFE3, Xp11.2 translocation, Gender, Prognosis

Ran Zhuo, Yiqi Zhu, Yanwen Lu, Wenliang Ma, Hongqian Guo, Weidong Gan. Impact of gender in clinicopathological features of Xp11.2 translocation renal cell carcinoma and clear cell renal cell carcinoma[J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(02): 105-109.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2023.02.002

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2023/V17/I02/105

Figures/Tables 4

References 25

[1]	Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update[J]. Eur Urol, 2019, 75(5): 799-810.
[2]	Baniak N, Barletta JA, Hirsch MS. Key renal neoplasms with a female predominance[J]. Adv Anat Pathol, 2021, 28(4): 228-250.
[3]	Liu N, Yi C, Gan W, et al. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma[J]. Clin Transl Med, 2022, 12(4): e797.
[4]	Pederzoli F, Bandini M, Marandino L, et al. Targetable gene fusions and aberrations in genitourinary oncology[J]. Nat Rev Urol, 2020, 17(11): 613-625.
[5]	Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults[J]. Eur Urol, 2006, 49(5): 798-805.
[6]	Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
[7]	Simonaggio A, Ambrosetti D, Vano YA, et al. MiTF/TFE translocation renal cell carcinomas: from clinical entities to molecular insights[J]. Int J Mol Sci. 2022, 23(14): 7649.
[8]	Dong X, Chen Y, Gan W, et al. Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma[J]. Front Oncol, 2022, 12: 1017425.
[9]	Ge Y, Lin X, Zhang Q, Li Z, et al. Xp11.2 translocation renal cell carcinoma with tfe3 rearrangement: Distinct morphological features and prognosis with different fusion partners[J]. Front Oncol, 2021, 11: 784993.
[10]	Scelo G, Li P, Chanudet E, et al. Variability of sex disparities in cancer incidence over 30 years: The striking case of kidney cancer[J]. Eur Urol Focus, 2018, 4(4): 586-590.
[11]	Mancini M, Righetto M, Baggio G. Gender-related approach to kidney cancer management: Moving forward[J]. Int J Mol Sci, 2020, 21(9):3378.
[12]	Lucca I, Klatte T, Fajkovic H, et al. Gender differences in incidence and outcomes of urothelial and kidney cancer[J]. Nat Rev Urol, 2015, 12(10): 585-92.
[13]	Choo MS, Jeong CW, Song C, et al. Clinicopathologic characteristics and prognosis of xp11.2 translocation renal cell carcinoma: Multicenter, propensity score matching analysis[J]. Clin Genitourin Cancer, 2017, 15(5): e819-e825.
[14]	Pereira G, Dória S. X-chromosome inactivation: implications in human disease[J]. J Genet, 2021, 100(2): 63.
[15]	Liu N, Wang Z, Gan W, et al. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: Clinical features, treatments and prognosis[J]. PLoS One, 2016,11(11): e0166897.
[16]	Rampersaud EN, Klatte T, Bass G, et al. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma[J]. Urol Oncol, 2014, 32(1): 30.
[17]	Hagerty BL, Aversa J, Diggs LP, et al. Characterization of alveolar soft part sarcoma using a large national database[J]. Surgery, 2020, 168(5):825-30.
[18]	Zhuang W, Liu N, Guo H, et al. Gender difference analysis of Xp11.2 translocation renal cell carcinomas's attack rate: a meta-analysis and systematic review[J]. BMC Urol, 2020, 20(1): 130.
[19]	Fucic A, Gamulin M, Ferencic Z, et al. Environmental exposure to xenoestrogens and oestrogen related cancers: reproductive system, breast, lung, kidney, pancreas, and brain[J]. Environ Health, 2012, 11 (Suppl 1):S8.
[20]	Wang Y, Yang Z, Han Z, et al. Estrogen receptor beta increases clear cell renal cell carcinoma stem cell phenotype via altering the circPHACTR4/miR-34b-5p/c-Myc signaling[J].FASEB J, 2022, 36(2):e22163.
[21]	Yedidia-Aryeh L, Goldberg M. The Interplay between the Cellular Response to DNA Double-Strand Breaks and Estrogen[J]. Cells, 2022, 11(19): 3097.
[22]	Shi Q,Liu N, Gan W, et al. Estradiol increases risk oftopoisomerase IlB-mediated DNA strand breaks toinitiate Xp11.2 translocation renal cell carcinoma[J]. Cell Commun Signal, 2021, 19(1): 114.
[23]	Peired AJ, Campi R, Romagnani P, et al. Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence[J]. Cancers, 2021, 13(18): 4588.
[24]	Aron M, Nguyen MM, Stein RJ, et al. Impact of gender in renal cell carcinoma: an analysis of the SEER database[J]. Eur Urol, 2008, 54(1): 133-140.
[25]	Peired AJ, Campi R, Romagnani P, et al. Sex and gender differences in kidney cancer: Clinical and experimental evidence[J]. Cancers, 2021, 13: 4588.

组别	例数	发病年龄[岁，(±s)]	患肾侧别(例)		手术方式(例)		肿瘤最大径[cm，(±s)]	T分期(例)		AJCC分期(例)		核分级(例)
组别	例数	发病年龄[岁，(±s)]	右	左	根治	部分	肿瘤最大径[cm，(±s)]	1~2	3~4	1~2	3~4	1~2	3~4
男性	22	39±17	7	15	12	10	5.3±2.4	15	7	15	7	6	16
女性	31	35±13	21	10	19	12	5.5±3.1	24	7	19	12	12	19
统计值		t=0.849	χ²=6.664		χ²=0.241		t=-0.275	χ²=0.565		χ²=0.266		χ²=0.750
P值		0.400	0.010		0.623		0.784	0.452		0.606		0.386

组别	例数	发病年龄[岁，(±s)]	患肾侧别(例)		手术方式(例)		肿瘤最大径[cm，(±s)]	T分期(例)		AJCC分期(例)		核分级(例)
组别	例数	发病年龄[岁，(±s)]	右	左	根治	部分	肿瘤最大径[cm，(±s)]	1~2	3~4	1~2	3~4	1~2	3~4
男性	22	39±17	7	15	12	10	5.3±2.4	15	7	15	7	6	16
女性	31	35±13	21	10	19	12	5.5±3.1	24	7	19	12	12	19
统计值		t=0.849	χ²=6.664		χ²=0.241		t=-0.275	χ²=0.565		χ²=0.266		χ²=0.750
P值		0.400	0.010		0.623		0.784	0.452		0.606		0.386

组别	例数	发病年龄[岁，(±s)]	患肾侧别(例)		手术方式(例)		肿瘤最大径[cm，(±s)]	T分期(例)		AJCC分期(例)		核分级(例)
组别	例数	发病年龄[岁，(±s)]	右	左	根治	部分	肿瘤最大径[cm，(±s)]	1~2	3~4	1~2	3~4	1~2	3~4
男性	121	58±13	68	53	35	86	5.2±2.9	101	20	102	19	87	34
女性	52	58±10	30	22	20	32	5.6±2.3	50	2	50	2	42	10
统计值		t=-0.089	χ²=0.033		χ²=1.525		t=0.222	χ²=5.271		χ²=4.794		χ²=1.058
P值		0.948	0.856		0.217		0.392	0.022		0.029		0.219

组别	例数	发病年龄[岁，(±s)]	患肾侧别(例)		手术方式(例)		肿瘤最大径[cm，(±s)]	T分期(例)		AJCC分期(例)		核分级(例)
组别	例数	发病年龄[岁，(±s)]	右	左	根治	部分	肿瘤最大径[cm，(±s)]	1~2	3~4	1~2	3~4	1~2	3~4
男性	121	58±13	68	53	35	86	5.2±2.9	101	20	102	19	87	34
女性	52	58±10	30	22	20	32	5.6±2.3	50	2	50	2	42	10
统计值		t=-0.089	χ²=0.033		χ²=1.525		t=0.222	χ²=5.271		χ²=4.794		χ²=1.058
P值		0.948	0.856		0.217		0.392	0.022		0.029		0.219

组别	例数	性别(例)		发病年龄[岁，(±s)]	患肾侧别(例)		手术方式(例)		肿瘤最大径[cm，(±s)]	T分期(例)		AJCC分期(例)		核分级(例)
组别	例数	男	女	发病年龄[岁，(±s)]	右	左	根治	部分	肿瘤最大径[cm，(±s)]	1~2	3~4	1~2	3~4	1~2	3~4
Xp11.2 tRCC	53	22	31	37±15	28	25	31	22	5.4±2.8	39	14	34	19	18	35
ccRCC	173	121	52	58±12	98	75	55	118	5.3±2.7	151	22	152	21	129	44
统计值		χ²=14.114		t=-8.023	χ²=0.240		χ²=12.268		t=0.199	χ²=5.685		χ²=15.658		χ²=29.419
P值		<0.001		<0.001	0.624		<0.001		0.842	0.017		<0.001		<0.001

Please choose a citation manager

Content to export